((自动化翻译由路透提供，请见免责声明 ))
9月19日 - ** 制药商旺达制药 股价盘前下跌10.9%，至4.41美元
** 该公司称，美国食品和药物管理局（FDA）拒绝了 (link) 批准其胃麻痹药物替替匹坦的申请。
** 该公司称 FDA 建议万达进行更多研究
** 将继续寻求批准该药物用于治疗胃瘫，胃瘫的特点是胃排空延迟
** 计划在今年晚些时候单独提交用于预防晕车呕吐的替替匹坦的上市申请
** 该公司股价今年累计上涨 17.3%，而纳斯达克生物技术指数 上涨 11.3
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.